Ace­lyrin's IL-17 in­hibitor fails to hit pri­ma­ry end­point in key study af­ter splashy IPO

Ace­lyrin said Mon­day that its lead drug izok­ibep failed to meet the pri­ma­ry end­point in a Phase IIb/III tri­al in pa­tients with hidradeni­tis sup­pu­ra­ti­va — a chron­ic in­flam­ma­to­ry con­di­tion that caus­es painful nod­ules and ab­scess­es to form un­der the skin.

It’s the Los An­ge­les biotech’s first big clin­i­cal read­out since it went pub­lic in May, and the news was bru­tal to its shares $SLRN — they fell 64% in af­ter-hours trad­ing Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER